Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05709730
Active, not recruiting Observational

Follow-up of Cell Changes in the Cervix

NCT05709730 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska University Hospital
Phase
Observational
Started
2016-07-07
Last updated
2024-10-10

Condition(s) studied

Cancer of Cervix

Investigational drug(s) / intervention(s)

HPV genotyping

HPV genotyping: HPV genotyping of samples classified that were positive for "other HPV"

Study summary

The purpose of the study is to follow up on cell changes detected in the cervical cancer screening program, to investigate whether they are handled with adequate quality.

Eligibility

Sex
FEMALE
Min age
23 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * women with an AGC diagnosis between February 17, 2014 and December 31, 2018 * 23-80 years old * resident of the Stockholm-Gotland region of Sweden Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Karolinska University Hospital Stockholm Sweden

More Karolinska University Hospital trials in Sweden

Ablation of Fibrotic Areas in Patients With Persistent Atrial Fibrillation. Active, not recruiting
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases Recruiting
Timing of Renal Replacement Therapy in the Critically Ill Patients Recruiting
TENS for Relief of Postoperative Pain in Orthopedic Patients Active, not recruiting
Resection or Ablation of Small Kidney Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05709730 on ClinicalTrials.gov ↗ ← All trials in Sweden